These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 628799)

  • 21. [Diffuse fibrosing alveolitis (author's transl)].
    Strumeliev S
    Z Erkr Atmungsorgane; 1981 May; 157(2):147-51. PubMed ID: 7032088
    [No Abstract]   [Full Text] [Related]  

  • 22. Fibrosing alveolitis: a report of 61 cases seen over the past five years.
    Jindal SK; Malik SK; Deodhar SD; Sharma BK
    Indian J Chest Dis Allied Sci; 1979; 21(4):174-9. PubMed ID: 549853
    [No Abstract]   [Full Text] [Related]  

  • 23. The management of cryptogenic fibrosing alveolitis in three regions of the United Kingdom.
    Johnston ID; Gomm SA; Kalra S; Woodcock AA; Evans CC; Hind CR
    Eur Respir J; 1993 Jun; 6(6):891-3. PubMed ID: 8339811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subacute diffuse fibrosing alveolitis (Hamman-Rich syndrome).
    Smith CC
    Br J Clin Pract; 1972 Apr; 26(4):151-8. PubMed ID: 5036482
    [No Abstract]   [Full Text] [Related]  

  • 25. Idiopathic pulmonary fibrosis in a young patient.
    Gomes MF; de Sousa GV; Nogueira JB
    Eur J Intern Med; 2008 Jan; 19(1):70-1. PubMed ID: 18206609
    [No Abstract]   [Full Text] [Related]  

  • 26. [Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression].
    Entzian P
    Pneumologie; 1998 Jul; 52(7):396-7. PubMed ID: 9738391
    [No Abstract]   [Full Text] [Related]  

  • 27. [Respiratory mechanics in patients with stage III pulmonary sarcoidosis and idiopathic fibrosing alveolitis: similarities and differences].
    Bogorodskaia EM; Evfim'evskiĭ VO; Borisov SE
    Probl Tuberk Bolezn Legk; 2006; (4):41-5. PubMed ID: 16813060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A case of cryptogenic fibrosing pneumonitis, successfully treated with large doses of steroids, and maintained without recurrence for five years (author's transl)].
    Ozawa K; Kawaguchi T; Kobayashi T; Mochizuki I; Kusama S; Kamiyama K; Shirosaki T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1980 Apr; 18(4):260-6. PubMed ID: 7392329
    [No Abstract]   [Full Text] [Related]  

  • 29. [The hemostatic system and correction of its impairments, by using the disaggregatory agent ticlopidine and low-molecular-weight heparin in patients with idiopathic fibrosing alveolitis].
    Vasil'ev SN; Stepanian IE; Kaminskaia GO; Serebrianaia BA; Shmelev EI
    Probl Tuberk Bolezn Legk; 2005; (6):49-55. PubMed ID: 16078724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Desquamative fibrosing alveolitis unresponsive to steroid or cytotoxic therapy.
    Barnes SE; Godfrey S; Millward-Sadler GH; Roberton NR
    Arch Dis Child; 1975 Apr; 50(4):324-7. PubMed ID: 1147673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Idiopathic fibrosing alveolitis].
    Neklasov IuF; Kachan LV; Guliaeva NV
    Probl Tuberk; 1984 Aug; (8):69-71. PubMed ID: 6494128
    [No Abstract]   [Full Text] [Related]  

  • 32. [What is safe in the therapy of alveolitis and lung fibrosis?].
    Lanser K; von Wichert P
    Internist (Berl); 1984 Dec; 25(12):735-40. PubMed ID: 6394536
    [No Abstract]   [Full Text] [Related]  

  • 33. Medical treatment of chronic hepatitis. Results of a retrospective study.
    Thaler H
    Tokai J Exp Clin Med; 1980 Jul; 5(3):361-6. PubMed ID: 7222126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Idiopathic fibrosing alveolitis in therapeutic practice].
    Rebrov AP; Panomareva EIu; Chesnokova EV; Chushinskiĭ SA
    Klin Med (Mosk); 2002; 80(9):63-5. PubMed ID: 12416231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapy of idiopathic diffuse pulmonary fibrosis].
    Schlehe H; Konietzko N; Altenstetter F; Matthys H
    Schweiz Med Wochenschr; 1973 Nov; 103(44):1543-7. PubMed ID: 4752205
    [No Abstract]   [Full Text] [Related]  

  • 36. [The role of phagocytic cells in the pathogenesis of idiopathic fibrosing alveolitis].
    Pokhodzeĭ IV; Bulychev AG; Ses' TP; Leont'eva EA
    Probl Tuberk; 1991; (4):10-3. PubMed ID: 1649475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical signs for the evaluation of the severity of idiopathic fibrosing alveolitis with special reference to the dependence of velco rales--so-called state sign].
    Cegla UH
    Prax Klin Pneumol; 1983 Oct; 37 Suppl 1():802-4. PubMed ID: 6647341
    [No Abstract]   [Full Text] [Related]  

  • 38. Cessation of steroids in renal allograft recipients on combined cyclosporine A, azathioprine, and prednisolone.
    O'Connell P; d'Apice A; Walker R; Francis D; Kincaid-Smith P
    Transplant Proc; 1988 Feb; 20(1):11-3. PubMed ID: 3278450
    [No Abstract]   [Full Text] [Related]  

  • 39. Cryptogenic fibrosing alveolitis predating ulcerative colitis.
    Pérez de Llano LA; Lancho A; Soilán del Cerro JL; López-Róses L
    Am J Gastroenterol; 1996 Apr; 91(4):822-3. PubMed ID: 8677973
    [No Abstract]   [Full Text] [Related]  

  • 40. Pulmonary hypertension in a patient with diffuse fibrosing alveolitis due to rheumatoid arthritis.
    Skwarski K; Zieliński J
    Cor Vasa; 1986; 28(3):206-9. PubMed ID: 3743089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.